1. Home
  2. RNTX vs AIRT Comparison

RNTX vs AIRT Comparison

Compare RNTX & AIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Logo Air T Inc.

AIRT

Air T Inc.

N/A

Current Price

$21.26

Market Cap

56.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
RNTX
AIRT
Founded
2001
1980
Country
United States
United States
Employees
10
646
Industry
Biotechnology: Pharmaceutical Preparations
Air Freight/Delivery Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
56.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RNTX
AIRT
Price
$1.17
$21.26
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
1.1M
2.4K
Earning Date
05-15-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$15.97
52 Week High
$2.22
$26.70

Technical Indicators

Market Signals
Indicator
RNTX
AIRT
Relative Strength Index (RSI) 40.78 44.40
Support Level $1.08 $20.85
Resistance Level $1.30 $23.82
Average True Range (ATR) 0.15 0.63
MACD -0.05 -0.10
Stochastic Oscillator 15.45 37.64

Price Performance

Historical Comparison
RNTX
AIRT

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

Share on Social Networks: